Safety and feasibility of minimally invasive surgical interventions for esophageal and gastric cancer in the acute setting
Dutch researchers found in a recent study that minimally invasive surgery in gastric cancer is safe, feasible and offers comparable short-term outcomes... Read More
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer
Integrating interdisciplinary supportive care into the treatment of metastatic gastric cancer enhances survival benefits, a recent study published in the Journal of... Read More
Dynamic, personalized treatment approach may improve outcomes in gastroesophageal cancers
A University of Chicago study found that when treatments are customized for gastric cancer patients based on the genetic characteristics of their... Read More
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
MD Anderson researchers identified two subtypes of peritoneal carcinomatosis, a form of gastric cancer, and developed gene expression signatures that can be... Read More
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
Gastric cancer patients who are malnourished prior to treatment faced worse treatment outcomes compared to those who maintained proper nutrition, according to... Read More
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
The PD-L1 inhibitor Bavencio, when given as maintenance therapy to gastric cancer patients in a trial, was not superior to chemotherapy, but... Read More
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer slowed down... Read More
